Rossby Financial LCC Acquires New Shares in Novo Nordisk A/S (NYSE:NVO)

Rossby Financial LCC acquired a new stake in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm acquired 8,311 shares of the company's stock, valued at approximately $715,000.

A number of other institutional investors have also made changes to their positions in the company. Center for Financial Planning Inc. lifted its position in shares of Novo Nordisk A/S by 72.4% during the fourth quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares during the last quarter. Albion Financial Group UT grew its stake in shares of Novo Nordisk A/S by 121.4% in the fourth quarter. Albion Financial Group UT now owns 507 shares of the company's stock worth $44,000 after purchasing an additional 278 shares in the last quarter. Sound Income Strategies LLC increased its stake in shares of Novo Nordisk A/S by 82.1% during the fourth quarter. Sound Income Strategies LLC now owns 539 shares of the company's stock valued at $46,000 after acquiring an additional 243 shares during the period. Hager Investment Management Services LLC acquired a new position in shares of Novo Nordisk A/S during the 4th quarter valued at $46,000. Finally, Halbert Hargrove Global Advisors LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth $47,000. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Trading Down 7.8 %

Novo Nordisk A/S stock traded down $4.89 during midday trading on Thursday, reaching $57.99. The stock had a trading volume of 32,192,935 shares, compared to its average volume of 5,952,675. The firm's fifty day simple moving average is $76.55 and its two-hundred day simple moving average is $92.55. The company has a debt-to-equity ratio of 0.62, a current ratio of 0.74 and a quick ratio of 0.55. Novo Nordisk A/S has a twelve month low of $57.36 and a twelve month high of $148.15. The firm has a market cap of $260.23 billion, a price-to-earnings ratio of 17.63, a PEG ratio of 0.90 and a beta of 0.61.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last issued its quarterly earnings results on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, beating analysts' consensus estimates of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Investors of record on Monday, March 31st were issued a dividend of $0.7874 per share. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a dividend yield of 1.2%. The ex-dividend date of this dividend was Monday, March 31st. Novo Nordisk A/S's dividend payout ratio (DPR) is currently 49.54%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. BNP Paribas started coverage on Novo Nordisk A/S in a report on Tuesday. They set an "underperform" rating on the stock. StockNews.com cut shares of Novo Nordisk A/S from a "strong-buy" rating to a "buy" rating in a research note on Tuesday. Kepler Capital Markets upgraded shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They issued an "equal weight" rating on the stock. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research note on Monday, January 6th. One investment analyst has rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of "Hold" and a consensus price target of $135.00.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.